Tweet
By Reuters, Wire Service Content. July 23, 2020, at 4:41 p.m.
BY JAN WOLFE
(Reuters) - Shares of Moderna Inc fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines, including a coronavirus vaccine.
An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts.
The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
... "At the end of the day, Arbutus might be able to claim a royalty in the [coronavirus] vaccine," Silbersher said.
... Arbutus shares more than doubled after the patent board posted its opinion on its electronic docket, to $6.20 on Nasdaq. Moderna shares lost 9.5% to end at $75.33, also on Nasdaq.
BY JAN WOLFE
(Reuters) - Shares of Moderna Inc fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines, including a coronavirus vaccine.
An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts.
The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
... "At the end of the day, Arbutus might be able to claim a royalty in the [coronavirus] vaccine," Silbersher said.
... Arbutus shares more than doubled after the patent board posted its opinion on its electronic docket, to $6.20 on Nasdaq. Moderna shares lost 9.5% to end at $75.33, also on Nasdaq.